What is Zacks Small Cap’s Estimate for ARWR Q2 Earnings?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Equities researchers at Zacks Small Cap issued their Q2 2025 EPS estimates for Arrowhead Pharmaceuticals in a research note issued on Tuesday, December 3rd. Zacks Small Cap analyst D. Bautz forecasts that the biotechnology company will earn ($0.97) per share for the quarter. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($3.09) per share. Zacks Small Cap also issued estimates for Arrowhead Pharmaceuticals’ Q3 2025 earnings at ($0.99) EPS, Q4 2025 earnings at ($1.00) EPS and FY2027 earnings at ($2.61) EPS.

Other research analysts have also recently issued research reports about the company. Sanford C. Bernstein decreased their price target on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating for the company in a research note on Friday, November 29th. Royal Bank of Canada restated an “outperform” rating and set a $42.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Thursday, September 26th. Citigroup reduced their price target on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Wednesday, November 27th. Chardan Capital restated a “buy” rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, November 27th. Finally, HC Wainwright lifted their target price on shares of Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the stock a “buy” rating in a research report on Tuesday. One analyst has rated the stock with a sell rating, four have given a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Arrowhead Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $42.70.

Arrowhead Pharmaceuticals Price Performance

Shares of NASDAQ ARWR opened at $23.61 on Friday. The firm has a market cap of $2.94 billion, a P/E ratio of -4.70 and a beta of 0.91. Arrowhead Pharmaceuticals has a twelve month low of $17.05 and a twelve month high of $39.83. The company has a quick ratio of 6.74, a current ratio of 6.74 and a debt-to-equity ratio of 2.06. The company has a 50 day moving average of $20.61 and a 200 day moving average of $23.22.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Several large investors have recently added to or reduced their stakes in ARWR. Avoro Capital Advisors LLC increased its stake in shares of Arrowhead Pharmaceuticals by 3.9% in the second quarter. Avoro Capital Advisors LLC now owns 8,888,888 shares of the biotechnology company’s stock worth $231,022,000 after purchasing an additional 333,333 shares in the last quarter. State Street Corp boosted its holdings in Arrowhead Pharmaceuticals by 8.8% in the 3rd quarter. State Street Corp now owns 6,354,331 shares of the biotechnology company’s stock worth $123,083,000 after buying an additional 516,569 shares during the period. Geode Capital Management LLC increased its stake in Arrowhead Pharmaceuticals by 0.9% in the 3rd quarter. Geode Capital Management LLC now owns 2,964,119 shares of the biotechnology company’s stock worth $57,426,000 after buying an additional 26,171 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in Arrowhead Pharmaceuticals by 2.9% during the second quarter. Bank of New York Mellon Corp now owns 1,085,069 shares of the biotechnology company’s stock valued at $28,201,000 after acquiring an additional 30,086 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Arrowhead Pharmaceuticals by 1.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,006,935 shares of the biotechnology company’s stock valued at $19,504,000 after acquiring an additional 12,574 shares in the last quarter. Hedge funds and other institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.